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AbstrAct:
Suppressor of cytokine signaling 1 (SOCS1) is frequently mutated in primary 
mediastinal and diffuse large B-cell lymphomas (DLBCL). Currently, the prognostic 
relevance of these mutations in DLBCL is unknown. To evaluate the value of the 
SOCS1 mutation status as a prognostic biomarker in DLBCL patients, we performed 
full-length SOCS1 sequencing in tumors of 154 comprehensively characterized DLBCL 
patients. We identified 90 SOCS1 mutations in 16% of lymphomas. With respect to 
molecular consequences of mutations, we defined two distinct subtypes: those with 
truncating (major) and those with non-truncating mutations (minor), respectively. 
The SOCS1 mutated subgroup or the minor/major subtypes cannot be predicted on 
clinical grounds; however, assignment of four established gene-expression profile-
based classifiers revealed significant associations of SOCS1 major cases with germinal 
center and specific pathway activation pattern signatures. Above all, SOCS1 major 
cases have an excellent overall survival, even better than the GCB-like subgroup. 
SOCS1 minor cases had a dismal survival, even worse than the ABC gene signature 
group. The SOCS1 mutation subsets retained prognostic significance in uni- and 
multivariate analyses. Together our data indicate that assessment of the SOCS1 
mutation status is a single gene prognostic biomarker in DLBCL.
IntroductIon
Diffuse large B-cell lymphoma (DLBCL) is a 
heterogeneous group of rapidly growing neoplasms 
with an aggressive clinical course. An intensive multi-
agent chemotherapy can cure ~40% of patients and 
the combination with anti-CD20 therapy has further 
improved outcome for additional 10-25% of patients [1-
4]. Despite the marked progress in treatment response 
of DLBCL, 30% of patients remain with refractory, 
often incurable disease [2,5]. The variability in DLBCL 
outcome raises the question how one can identify these 
patient subsets. Currently, only few prognostic models 
that predict outcomes based on clinical data have been 
proposed [6,7]. Tissue-based classification schemes 
[8,9] take expression of distinct proteins into account to 
predict clinical course and treatment response in DLBCL 
patients; however, these do not adequately reflect the 
heterogeneity of DLBCL. To get a handle on the diversity 
of DLBCL several gene expression based classifiers have 
been devised [10-13]. The most widely used molecular 
subclassification [10] divides DLBCL into at least three 
prognostic relevant subtypes: one clinically aggressive 
subset that demonstrates a profile similar to activated 
peripheral blood B-cells (ABC), a second subtype with a 
better prognosis that is similar to normal germinal center 
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B-cells (GCB), and a third subtype, referred to as PMBL 
[14] with an outcome that is superior to all other DLBCL 
subtypes [15,16]. While gene expression profiling can 
help to refine DLBCL classification into GCB, ABC, and 
PMBL subtypes with survival differences in patients [17], 
its use in clinical practice is not yet routine.
Suppressor of cytokine signaling 1 (SOCS1) is 
frequently mutated in PMBL [18] and other lymphomas 
[19]. SOCS1 inhibits janus kinase (JAK)/signal transducer 
and activator of transcription (STAT) signaling [20].  The 
C-terminal domain including the SOCS box is necessary 
for this function [21] and we have shown that mutations 
affecting this domain result in abnormal stabilization of 
JAK2 and dysregulation of JAK/STAT signaling [18]. 
Although the specific role in lymphomagenesis remains 
to be elucidated, SOCS1 is a postulated tumor suppressor 
gene that is frequently inactivated by genomic mutations 
[22,20]. In case series and DLBCL cell lines, other groups 
have described SOCS1 mutations [23-25]; however, the 
prognostic relevance of SOCS1 mutations in DLBCL has 
not been addressed.
The aim of the present study was to assess the value 
of the SOCS1 mutation status as a prognostic biomarker 
in a well-characterized cohort of DLBCL patients. We 
found that SOCS1 mutation subtypes disclose significant 
differences in outcome. Thereby, assessment of the SOCS1 
mutation status represents a novel tumor-derived, single 
gene prognostic biomarker in DLBCL.
results
SOCS1 mutations in DLBCL are frequent and do not 
cluster at mutational hotspots. Full-length sequencing of 
SOCS1 revealed mutations in 24 (16%) of the 154 DLBCL 
samples (Table 1). Figure 1 summarizes the position and 
types of all SOCS1 mutations within the coding region 
(detailed information in Supplemental Figure 1 and 
Supplemental Table 1). In total, we found 90 unique 
mutational events in these 24 individual cases (referred 
to as SOCS1 mutant). Five of 24 SOCS1 mutant cases 
carried a single mutation, whereas multiple mutations 
accumulated in the majority of cases. Mapping of the 
SOCS1 mutations over the coding region and comparison 
with annotated mutations in the COSMIC database (Figure 
2) demonstrated that mutations are spread throughout 
the coding region (Figure 2B). Although some domains 
were more frequently affected (Supplemental Table 2), 
there were no mutational hotspots. Specifically, SOCS1 
mutations in DLBCL mainly affected the region encoding 
the JAK domain and therein the kinase inhibitory region 
(KIR) and Src homology 2 (SH2) subdomains. In addition, 
we noted that mutations are rarely located primarily in 
C-terminal domains; however, when consequences of 
(5’) upstream mutations were taken into account (Figure 
2C), the fraction of cases with predicted alterations 
in C-terminal domains increased substantially. The 
deleterious impact of truncations and/or frameshifts that 
alter longer stretches of the gene, affected in particular 
Figure 1: SOCS1 Mutations in dlbcl. SOCS1 sequences of mutated DLBCL plotted and sorted by number and predicted severity 
of mutations (top row, encoded domains over coding regions). SOCS1 coding region (length: 636bp) of each mutated samples is represented 
by a black line and symbols visualize the type and site of each mutation. Grey lines represent nonsense sequence after a mutation site, when 
appropriate. Circles are replacement substitutions, squares are silent mutations, diagonal lines are deletions, a box represents duplication, 
and vertical lines symbolize premature stop codons. Symbols are red when mutations occurred at consensus sites for somatic hypermutation. 
Note that SOCS1 mutations are randomly distributed within the coding region. Abbreviations: SH3, Src homology 3; JAK, Janus kinase; 
NLS, nuclear localization signal; SOCS box, silencer of cytokine signaling box.
N C
SH3 JAK Kinase Domain NLS SOCS Box
SOCS1 Minor (n=12)
SOCS1 Major (n=12)
5’ 3’
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the SOCS box (range 35-50% of SOCS1 mutant DLBCL). 
Thus, SOCS1 C-terminal domains are rarely affected 
by primary events; however, C-terminal domains are 
frequently mutated or lost due to more severe upstream 
mutations (detailed mutation frequencies are provided in 
Supplemental Table 2). Consequently, SOCS1 sequence 
analysis implies different degrees of mutational severity, 
which can be visualized via the length of intact coding 
sequence (Figure 1). Accordingly, we defined SOCS1 
minor as cases that harbor only non-foreshortening point 
mutations (12 of 24 SOCS1 mutated cases in our cohort), 
and the SOCS1 major group as cases with truncating 
mutations or deletions that affect presence or position of 
C-terminal domains (12 of 24 SOCS1 mutated cases in our 
cohort; Figure 2C). To account for these differences, we 
performed subgroup analyses based on the two mutation 
subtypes (SOCS1 minor vs. major).
SOCS1 mutations preferentially occur at somatic 
hypermutation motifs. A previous study has postulated 
that SOCS1 mutations might be the result of somatic 
hypermutation [25]. We checked the hotspot consensus 
motifs (RGYW/WRCY, DGYW/WRCH and WA/TW) 
known as somatic hypermutation target sites that result 
in single nucleotide substitutions (for details see methods 
and supplement). The numbers of point mutations per 
case ranged from 1-18 (Supplemental Table 3) and 
accumulated in the somatic hypermutation motifs (40,8 
%). G/C nucleotides (n=64) were targeted more frequently 
compared to A/T (n=12) nucleotides (26 vs. 5 in somatic 
hypermutation motifs). In cases MPI-109 and MPI-
153, one flanking region of each deletion was a somatic 
hypermutation site (Supplemental Figure 1, Supplemental 
Table 1). The frequency, location, and translational 
consequence of SOCS1 mutations in our data sustain the 
hypothesis that these mutations are caused by aberrant 
somatic hypermutation.
SOCS1 mutation status cannot be predicted on 
clinical grounds. Clinical characteristics of 154 DLBCL 
patients were analyzed with respect to their co-occurrence 
with SOCS1 mutations. Table 2 lists the clinical and 
pathological features of SOCS1 mutant DLBCL patients. 
The immunophenotype of SOCS1 mutant DLBCL was 
characterized by presence of BCL2 (18/24, 75.0%) 
and BCL6 expression (23/23, 100.0% of evaluable 
cases).  CD10 was expressed in 7 of 24 (29.2%), and 
MUM1 in 12 of 22 (54.5% of evaluable cases). Ki-67 
immunostaining of SOCS1 mutant cases was variable 
but indicated a high proliferative rate.  Seven of 23 cases 
(30.4%) displayed a BCL6 breakpoint by FISH analysis. 
Furthermore, comparison of SOCS1 wild-type vs. SOCS1 
mutation subtypes did not allow discrimination based 
on any specific clinicopathological feature (Table 3).  In 
consequence, the SOCS1 status cannot be inferred from a 
basic panel of clinical parameters.
SOCS1 major mutations exhibit the GCB gene 
expression signature. We correlated four established gene 
table 1: demographic and clinical 
characteristics of the study cohort 
screened for SOCS1 Mutations
characteristic Patient cohort n=154 %
Age, years 
Median (Range) 64.5 (3-93)
<60 years 62 40.3
≥60 years 92 59.7
sex
Male 92 59.7
Female 62 40.3
Ann Arbor stage
I and II 48 43.6
III and IV 62 56.4
lesions
EN only 20 20
N only 55 55
EN + N 25 25
b symptoms
Absent 55 57.3
Present 41 42.7
IPI-score*
0 12 10.5
1 49 43
2 31 27.2
>2 22 19.3
chemotherapy
ALL-like 13 11.5
CHOP-like 74 65.5
Other 15 13.3
None 11 9.7
radiotherapy
No 80 74.8
Yes 27 25.2
treatment response
CR+CRu 54 60.0
nC/SD 2 2.2
PR 15 16.7
PD 19 21.1
relapse
No 104 86.0
Yes 17 14.0
Abbreviations: ALL, acute lymphoblastic leukemia; 
CHOP, cyclophosphamide, doxorubicin, vincristine and 
prednisolone; CR, complete response; CRu, complete 
response unconfirmed; EN, extranodal; n, total number; N, 
nodal; nC/SD, no change/stable disease; PD, progressive 
disease; PR, partial response/resmission; IPI, international 
prognostic index.  *for some patients not all IPI 
characteristics were available [i.e., a missing factor was 
set to “absent” (0); therefore some patients with IPI 0/1 
may have higher IPI-scores; see supplemental figure 2E]
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expression classifications (COO, mBL, CC, PAP) with the 
presence of SOCS1 mutations (Table 4). Each expression-
based signature captures a different aspect of DLBCL 
biology that may track with the SOCS1 mutation status.
The COO signature divided the 24 SOCS1 mutant cases 
into 19 (79.2%) GCB-like lymphomas and 5 (20.8%) non-
GCB lymphomas. Strikingly, all 12 SOCS1 major cases 
show a GCB signature, whereas those with SOCS1 minor 
mutations showed no trend for a specific COO signature. 
SOCS1 mutation status was at least in this DLBCL 
cohort not associated with the mBL signature (Table 4). 
Additionally, SOCS1 mutations did not occur uniformly 
distributed over the PAP classification scheme (P=0.003; 
Fisher’s exact test). Specifically, 12 SOCS1 mutant cases 
displayed the PAP-1 signature [n=12 (32%) of all 37 PAP-
1 vs. n=12 (10%) of all 117 non-PAP-1; P=0.003].  Further 
analysis by SOCS1 mutation subtype revealed that 58.3% 
of the SOCS1 major cases display the PAP-1 pattern. 
There was no specific association with any CC signature 
(i.e. OxPhos, BCR, HR) in SOCS1 mutant, SOCS1 major 
Figure 2: SOCS1 Mutation Frequency. A. SOCS1 coding region depicted as scheme of functional domains.  B. Frequency map 
compares regional distribution of SOCS1 mutations in DLBCL cases from our cohort (purple bars, N=24) and all SOCS1 mutated 
cases form the COSMIC database (grey bars, N=31); there are no mutational hotspots. While the KIR and SH2 regions within the JAK 
domain were frequently affected, mutations directly affecting the C-terminal SOCS box were rarely seen.  C. Fraction of cases affected 
by downstream consequences of 5’ mutations. The plot was constructed considering a range of predicted functional consequences of 
length-altering mutations (i.e., truncating and/or frameshift mutations) on downstream domains. The bottom line indicates a ‘conservative’ 
weighing where only the complete lack of C-terminally encoded domains is considered a deleterious event whereas in the top line, a more 
‘aggressive’ weighing also accounted for alterations in domain position or partial disruptions of domains. Thus, the range between lines 
symbolizes the predicted spectrum of encoded downstream consequences of 5’ mutations.  Shown is a comparison of our study cohort 
(purple) and the COSMIC database (grey).  Based on these graphs, cases with truncating or deleterious mutations that affected presence 
or position of C-terminal domains were considered SOCS1 major whereas those cases with non-truncating/non-foreshortening mutations 
(i.e., point mutations) were considered SOCS1 minor.  D. Subgroup analysis of regional distribution of SOCS1 major mutations in our 
DLBCL cohort (red; N=12) in comparison to major cases in the COSMIC database (grey; N=23). Note the absence of mutational hotspots. 
E. Fraction of 5’ C-terminal consequences in SOCS1 major subgroup in our cohort (red) and in the COSMIC database (grey).  F. Fraction 
of mutations in the SOCS1 minor subgroups in our cohort (blue, N=12) and the COSMIC database (grey, N=3).
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or SOCS1 minor DLBCL cases. Together, examination 
of four established expression signatures revealed that 
SOCS1 mutant cases and in particular SOCS1 major cases 
accumulate in GCB and PAP-1 lymphomas. Notably, all 
SOCS1 major cases harbored the GCB signature. 
SOCS1 major and minor mutated cases differ 
in clinical outcome. At the time of data evaluation, 
clinical follow up information was available for 122 of 
154 patients (~80% of the cohort). The median follow-
up time of patients was 21.8 months (1.7 years; range: 
0-22.3 years). Seventy-eight patients had died of disease 
(~51%) and 46 patients were either alive or lost to follow-
up (censored). Based on combination chemotherapy 
carried out in the pre-rituximab era, the patients were 
not uniformly treated (Table 1) [11,26]. There was no 
difference in overall survival between SOCS1 mutant 
and SOCS1 wild-type cases (Figure 3A, P = 0.45). 
Interestingly, the subgroups SOCS1 major and SOCS1 
minor showed marked survival differences to SOCS1 
wild-type patients, however, in different directions: While 
overall survival was longer in patients with lymphomas 
that harbor SOCS1 major mutations, it was shorter in 
patients with SOCS1 minor mutations (Figure 3A). 
For quantitative comparison of prognostic effects, we 
determined the log hazard ratios using univariate Cox 
proportional hazard regression models (Figure 4A). In 
line with Figure 3, we observed that SOCS1 gene mutation 
status by itself has little prognostic impact; however, 
SOCS1 mutation subtypes herald different prognostic 
fates. More importantly, the comparison of hazard ratios 
across prognostic predictors showed that the SOCS1 status 
is a strong factor. It is due to these strong effects that the 
SOCS1 status reached statistical significance in spite of the 
relatively small number of cases in these two subgroups. 
Patients with GCB-like lymphomas have a better 
prognosis than those with ABC-like lymphomas [10]. 
Notably, all our SOCS1 major cases were of the GCB-
like type, suggesting that this might explain the survival 
difference. We plotted Kaplan-Meier curves for overall 
survival of SOCS1 major and SOCS1 minor against the 
SOCS1 wild-type subgroup that we additionally separated 
into GCB- and ABC subgroups (Figure 3B). These curves 
suggest that SOCS1 major cases carry a good prognosis 
also when compared to GCB-SOCS1 wild-type cases 
only, whereas SOCS1 minor cases have a poor prognosis 
even when compared to ABC-SOCS1 wild-type cases. 
Moreover, the prognostic value of the COO signature 
remains intact when reduced to SOCS1 wild-type cases 
suggesting that it cannot be attributed to the SOCS1 
mutation status alone. We corroborated this observation 
in a multivariate Cox model.  With respect to outcome, 
the SOCS1 mutation status had significant prognostic 
information independent of the covariates age, AAS, 
and COO signature (Figure 4B). Together these analyses 
demonstrated that SOCS1 major status is a predictor for 
better survival whereas SOCS1 minor status is a predictor 
for worse survival. 
dIscussIon 
Here, we evaluated the prognostic value and 
molecular characteristics of SOCS1 mutations in a 
well-characterized cohort of 154 DLBCL patients. We 
show that SOCS1 mutational subtypes are associated 
with divergent outcomes as well as distinct expression 
signatures. Thereby, SOCS1 mutation status is a novel 
tumor-derived, single gene biomarker with molecular and 
prognostic implications in DLBCL. 
Full-length SOCS1 sequencing revealed 90 
mutations in 24 of 154 DLBCL cases (16%), which is in 
line with SOCS1 mutation frequencies in smaller DLBCL 
series (7/26 [25] and 8/33 [24]). Recently, two groups 
reported genome-wide mutation analyses of DLBCL with 
highly concordant results [23,27]. Remarkably, whole-
exome sequencing disclosed SOCS1 gene mutations 
in three DLBCL patients [23]. Here, we observed the 
accumulation of single nucleotide substitutions at sites 
preferentially targeted by somatic hypermutation. Given 
that frequencies and patterns are compatible with other 
hypermutated genes [28], our findings support the notion 
that germinal-center experienced lymphomas are prone to 
acquire SOCS1 gene mutations by somatic hypermutation 
[25]. This conclusion has recently been confirmed using 
genome-wide approaches [29]. In addition, the spread of 
mutations over the coding region sustains the hypothesis 
that SOCS1 is a tumor suppressor [20].
From a clinical perspective, our key finding is that 
the prognosis of patients with SOCS1 mutations strongly 
depends on the nature of the mutation. We organized 
mutations by the lengths of intact encoded sequence 
(Figure 1, 2), thus splitting the cases in two groups: SOCS1 
major, which has a good prognosis and SOCS1 minor, 
which has a poor prognosis (Figure 3, 4). While these 
findings are promising, several aspects should be taken into 
account:  First, despite being the largest SOCS1 mutation 
study in DLBCL to date, the number of cases in mutated 
subgroups is relatively small. While this is a typical side 
effect of highly resolved molecular stratifications, the 
estimated hazard ratios were so large that the survival 
difference reached statistical significance both in uni- and 
multivariate analyses (Figure 4). Second, determination 
whether a specific mutation was mono- or biallelic was 
precluded due to the presence of varying amounts of non-
neoplastic cells in the tumor samples. This biologically 
imposed limitation should however not lessen the value 
of the biomarker and rather simplify the implementation 
process in terms of ease of diagnostic assessment. Third, 
we are not able to provide a specific biological explanation 
for the observed prognostic differences in the SOCS1 
mutation subgroups. It is tempting to hypothesize that the 
more severe, truncating mutations as seen in the SOCS1 
major cases result in loss of its inhibitory function (i.e., 
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table 2: clinicopathological characteristics of cases with SOCS1 Mutations
Id Age, sex
dlbcl 
subtype* Immunohistochemistry FIsH Gene expression signatures
CD10 BCL2 BCL6 MUM1 Ki-67 MYC BCL6 t(14;18) COO mBL PAP CC
MPI-
135 77, F ANA – + + + 99 – – – ABC non-mBL PAP-3 BCR
MPI-
202 72, M NOS – – + + 80 – + – GCB non-mBL PAP-1 HR
MPI-
166 54, M NOS + + + + 30 – – + GCB non-mBL mind-L BCR
MPI-
247 70, M CB – + + + 90 – + – un. non-mBL PAP-1 BCR
MPI-
030 59, M CB – + + + 60 – – – GCB non-mBL PAP-1 HR
MPI-
165 86, F NOS – – + – 95 nIG + – GCB Intermed mind-L BCR
MPI-
199 66, M CB – + + + 50 – – – ABC non-mBL PAP-1 HR
MPI-
063 73, F NOS – + + + NA – NA – un. non-mBL PAP-3 OxP
MPI-
092 58, F CB – + + + 65 – – – GCB non-mBL mind-L OxP
MPI-
157 40, M NOS – + + – 45 – + – un. non-mBL PAP-2 NA
MPI-
046 59, F NOS + + + – 80 nIG – + GCB Intermed PAP-3 BCR
MPI-
134 29, F CB – – + + 85 – – – GCB non-mBL PAP-1 HR
MPI-
105 60, F CB – + + – 75 – + – GCB non-mBL PAP-1 HR
MPI-
241 40, F NOS – + + – 80 – + – GCB non-mBL mind-L BCR
MPI-
122 18, M CB – + + + 90 – – – GCB non-mBL PAP-1 HR
MPI-
220 65, F NOS + + + NA 90 IG – – GCB mBL mind-L NA
MPI-
248 56, M IB + + + – 50 nIG – + GCB Intermed mind-L BCR
MPI-
136 32, M CB – + + – 95 – – – GCB non-mBL PAP-1 HR
MPI-
137 18, M NOS – + + + 85 – – – GCB non-mBL PAP-1 NA
MPI-
207 27, M NOS – – + + 70 – – – GCB non-mBL PAP-1 HR
MPI-
036 70, F CB + + + – 98 IG – + GCB Intermed mind-L BCR
MPI-
153 78, F CB – – NA NA 50 – + – GCB non-mBL PAP-1 BCR
MPI-
102 21, F NOS + + + – 80 nIG – – GCB non-mBL PAP-1 NA
MPI-
109 42, M CB + – + – 75 – – – GCB non-mBL PAP-4 BCR
Abbreviations: ABC, activated B cell; ANA, anaplastic; CB, centroblastic; CC, consensus cluster signature; COO, cell-of-origin signature; DLBCL, 
diffuse large B-cell lymphoma; F, female; FISH, fluorescence in situ hybridisation; GCB, germinal center B cell; HR, host-response; IB, immunoblastic; 
ID, MPI-number from MMML cohort [11]; IG, immunoglobulin rearrangement of MYC gene; Intermed., intermediate signature; Ki-67, proliferation 
index in percent; M, male; mBL, molecular-Burkitt signature; mind-L, molecularly individual lymphoma; NA, not available; nIG, non-IG type of MYC-
rearrangement; NOS, DLBCL not otherwise specified; OxPhos, oxidative-phosphorylative pathway; PAP, pathway activation pattern signature; t(14;18), 
BCL2-IGH translocation; un., unclassified; cut-offs for BCL2-, BCL6- and MUM1-negativity by immunohistochemistry were ≤25% and 0% for CD10-
negativity. *according to Hummel et al [11].
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table 3: clinical characteristics of Patient subsets based on SOCS1 status
Wt
(n=130)
SOCS1 Mut. 
(n=24)
SOCS1 Maj.
(n=12)
SOCS1 Min.
(n=12) P P P
characteristic no. % no. % no. % no. %
Wt 
vs. 
Mut.
Wt 
vs. 
Maj.
Wt 
vs. 
Min.
Age, years 
Median(Range) 66,0(3-93) 58.5 (18-86) 56.5 (18-78) 62.5 (29-86) 0.46 0.13 0.66
<60 48 36.9 14 58.3 8 66.7 6 50 0.07 0.06 0.37
≥60 82 63.1 10 41.7 4 33.3 6 50   
sex       0.37 0.54 0.54
Male 80 61.5 12 50 6 50 6 50   
Female 50 38.5 12 50 6 50 6 50   
Ann Arbor stage       1.0 1.0 1.0
I and II 41 44.1 7 41.2 4 44.4 3 37.5   
III and IV 52 55.9 10 58.8 5 55.6 5 62.5   
lesions    0.73 0.91 0.75
EN only 16 18.9 4 26.7 2 25 2 28.6   
N only 48 56.5 7 46.6 4 50 3 42.9   
EN + N 21 24.7 4 26.7 2 25 2 28.6   
b symptoms       0.40 0.28 1
Absent 48 59.3 7 53.8 3 37.5 4 57.1   
Present 33 40.7 8 61.5 5 62.5 3 42.9   
IPI-factors 0.79 0.5 1
0,1 51 51.5 10 58.8 6 66.6 4 50
≥2 46 46.5 7 41.2 3 33.3 4 50
chemotherapy       0.11 0.48 0.49
ALL-like 12 12.8 1 5.3 1 11.1 - -   
CHOP-like 59 62.8 15 78.9 7 77.8 8 80   
Other 13 13.8 2 10.5 1 11.1 1 10   
None 10 10.6 1 5.3 - - 1 10   
radiotherapy       1 0.24 0.44
No 66 75 14 73.7 5 55.6 9 90   
Yes 22 25 5 26.3 4 44.4 1 10   
treatment 
response       0.78 0.47 0.65
CR 36 47.4 7 50.0 6 66.7 1 20
CR, unconfirmed 9 11.8 2 14.3 1 11.1 1 20   
nC/SD 2 2.6 - - - - - -  
PR 13 17.1 2 14.3 1 11.1 1 20   
PD 16 21.1 3 21.4 1 11.1 2 40   
relapse       0.74 1.0 1.0
No 86 85.1 18 90 9 90 9 90  
Yes 15 14.9 2 10 1 10 1 10  
Abbreviations: ALL, acute lymphoblastic leukemia; CHOP, cyclophosphamide, doxorubicin, vincristine and 
prednisolone; CR, complete response; EN, extranodal; IPI, international prognostic index; Maj., major; Min.; 
minor; Mut., mutant; n, total number; N, nodal; nC, no change; No., number of cases; PD, progressive disease; 
PR, partial response; SD, stable disease; WT, wild-type; P values refer to Fisher’s exact test (including all 
characteristics except in chemotherapy: CHOP-like vs. non-CHOP and in treatment response CR/CR, unconfirmed 
vs. nC/SD/PR/PD).
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resulting in prolonged activation of JAK/STAT signaling). 
For example, from SOCS1 major mutated cell lines we 
know that this is the case [18,22]. However, one has to 
acknowledge that the prognostic differences are not 
necessarily a linear consequence of the underlying 
molecular pathology and clearly not of the natural course 
of the disease. Rather, we observe a composite effect 
that includes at least chemotherapy-induced alterations 
as well as variability in response to treatment. To guide 
the design and interpretation of future functional studies, 
we abstain from speculations and merely point out that 
SOCS1 major vs. SOCS1 minor mutations are associated 
with increased vs. reduced overall survival, respectively. 
Fourth, the retrospective nature of this study does not 
account for treatment advances achieved by rituximab 
[3]. Interestingly, to date the majority of established 
prognostic factors in DLBCL remained prognostic – also 
in R-CHOP based studies [1]. Therefore, the strength 
of the observed associations between SOCS1 mutation 
subtypes and overall survival makes SOCS1 sequence 
analysis a promising prognostic biomarker candidate in 
DLBCL. Finally, the lack of mutational hotspots requires 
Figure 3: Kaplan-Meier survival estimates According to SOCS1 Mutation status.  A. The presence of SOCS1 mutations 
(grey) in DLBCL patients was not associated with different overall survival compared to SOCS1 wild-type (black; =0.45).  Overall survival 
among patients with tumors harboring SOCS1 major mutations (red) was better when compared with SOCS1 wild-type (P=0.016).  DLBCL 
cases with SOCS1 minor mutations (blue) had a poor overall survival when compared to SOCS1 wild-type cases (P=0.003).  B. Relationship 
of overall survival according to SOCS1 mutation type and cell-of-origin expression signature. Clinical outcome of SOCS1 major patients 
(red line) differed significantly from patients with a GCB signature (orange line; P=0.03). Clinical outcome of patients with SOCS1 minor 
patients (dark blue line) was significantly worse when compared to patients with an ABC signature (light blue line; P=0.01). All P values 
from Cox regression models.
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that full-length sequencing of SOCS1 must be done to 
determine the SOCS1 mutation status. Due to the shortness 
of this 636bp gene, however, this is easily feasible (also 
from DNA extracted from formalin fixed, paraffin 
embedded tumor tissue) and, therefore, should encourage 
independent validation in a larger and rituximab-treated 
cohort. 
In summary, we have shown that SOCS1 mutation 
subtypes in DLBCL track with distinct gene expression 
signatures and predict divergent outcomes. Thereby the 
SOCS1 gene mutation status is a novel tumor-derived, 
single gene biomarker with prognostic relevance in 
DLBCL.
MAterIAl And MetHods
Regulatory Approval and Study Population. 
Ethics committees of all participating institutions 
approved the protocols of the network project “Molecular 
Mechanisms in Malignant Lymphoma” (MMML; 
see Supplemental Appendix 1). Descriptions of the 
MMML project protocols, histopathological review and 
classification according to WHO guidelines [30] have 
been part of prior publications with a different focus 
[11,26,31,32]. In this study the focus is SOCS1 mutation 
analysis in tumor samples from a consecutive cohort of 
well-characterized DLBCL patients. Table 1 lists the 
clinical characteristics of the cohort.
PCR design and SOCS1 sequencing. 
The SOCS1 gene is divided in two exon regions: 
Exon 1 (length:104 bp) contains the 5’ UTR (untranslated 
region) and exon 2 (length:1766 bp) contains part of 
the 5’ UTR, the translation initiation site (position 705), 
the stop codon (position 1340=c.636), and the 3’ UTR. 
Primers were M13-tailed (biomers.net, Ulm, Germany) 
and designed to capture a 761 bp PCR fragment covering 
the complete open reading frame (636bp):  exon2-forward 
primer 5’-CACCCCCGGACGCTATG and exon2-reverse 
primer 5’-CCACATGGTTCCAGGCAAGTA. After initial 
touchdown PCR, the amplification product was processed 
table 4: Gene-expression signatures of Patient subsets based on SOCS1 status.
Wt SOCS1 Mut. SOCS1 Major SOCS1 Minor P P P
signatures no. % no. % no. % no. % Wt vs. Mut.
Wt vs. 
Maj.
Wt vs. 
Min.
coo 0.0006 <0.001 0.23
GCB 51 39.2 19 79.2 12 100 7 58.3
ABC 47 36.2 2 8.3 - - 2 16.7
Uncl. 32 24.6 3 12.5 - - 3 25
mbl 1 0.6 1
mBL 9 6.9 1 4.2 1 8.3 - -
non-mBL 90 69.2 19 79.2 9 75 10 83.3
Interm. 31 23.8 4 16.7 2 16.7 2 16.7
cc 0.81 1 0.75
BCR 66 55.0 10 50.0 5 56 5 45.5
HR 38 31.7 8 40.0 4 44 4 36.4
OxPhos 16 13.3 2 10.0 - - 2 18.2
PAP 0.003 0.006 0.13
BL-PAP 10 7.7 - - - - - -
Mind-L 38 29.2 7 29.2 4 33.3 3 25
PAP-1 25 19.2 12 50.0 7 58.3 5 41.7
PAP-2 27 20.8 1 4.2 - - 1 8.3
PAP-3 21 16.2 3 12.5 - - 3 25
PAP-4 9 6.9 1 4.2 1 8.3 - -
Abbreviations: ABC, activated B cell; BCR, B cell receptor and activation; BL-PAP, Burkitt lymphoma-
pathway activation pattern; CC, consensus cluster; COO, cell-of-origin signature; GCB, geminal center B-cell; 
Interm., intermediate; HR, host-response; mBL, molecular Burkitt lymphoma defined as 95% similar to Burkitt 
lymphoma [11]; Mind-L, molecularly individual lymphoma; Mut., mutant; No., number of cases; Uncl., 
unclassified; non-mBL, less than 5% similarity to Burkitt lymphoma [11]; OxPhos, oxidative-phosphorylative 
pathway; PAP, pathway activation pattern; WT, wild-type; P values refer to Fisher’s exact test.
Oncotarget 2013; 4: 35-4744www.impactjournals.com/oncotarget
by agarose gel purification using the peqGOLD Gel 
Extraction Kit (peqlab, Erlangen, Germany). Sanger DNA 
sequencing employed the BigDye Terminator v3.1 Kit on 
a 3130 Genetic Analyzer (both ABI, Carlsbad, CA). Dye 
signals were translated by the KB™ Base Caller Software 
and visualized using the Sequencing Analysis Software 
v5.4 (both ABI).
SOCS1 sequence and mutation analysis. 
Forward and reverse sequences were manually 
analyzed by blasting the obtained sequence against the 
human SOCS1 sequence (ENST0000332029; SOCS1-
001; www.ensembl.org, last accessioned Oct 1th, 2012). 
After annotation of the nucleotide alterations, sequence 
information was translated into protein sequence (ExPASy 
translate tool, www.expasy.org/translate/, last accessed Oct 
1th 2012). Alterations were mapped over the open reading 
frame as well as the known SOCS1 protein domains 
(Figure 1, Supplemental Figure 1) [18,20,33,34]. By 
plotting previously published mutated cases in a similar 
fashion (www.sanger.ac.uk/genetics/CGP/cosmic; last 
accessed Oct 1th, 2012; SOCS1: status Sept 13th, 2011), 
we compared the distribution of sequence alterations 
(Figure 2). Additionally, the DNA sequence of mutated 
SOCS1 cases was used to analyze the targeting of the 
somatic hypermutation mechanism at specific hotspot 
motifs [28]. We used a DNA pattern search tool to identify 
somatic hypermutation hotspots (Gene Infinity LLC: 
http://www.geneinfinity.org/sms/sms_DNApatterns; last 
accessioned Oct 1th, 2012). Specifically, these preferred 
hotspots include RGYW/WRCY (G:C is the mutable 
position; R=purine, Y=pyrimidine, and W=A/T) [35], 
DGYW/WRCH (G:C is the mutable position; D=G/T/A; 
H=T/C/A) [36] and WA/TW (A:T is the mutable position) 
nucleotide pattern at both DNA strands [37]; see also 
supplement.
Gene expression signatures.
Prior characterization of cases employed in this 
study cohort included gene expression profiling on the 
Affymetrix U133A platform (Affymetrix, Santa Clara, 
CA, USA); data set GSE4475 is available at http://www.
Figure 4: Forest plot of log hazard ratios (Hr) for overall survival according to baseline clinical characteristics, 
assigned gene expression signatures and SOCS1 gene status as well as mutation types.  A. Univariate and B. multivariate Cox 
proportional hazards regression models.  Abbreviations: AAS, Ann Arbor Stage; IPI, international prognostic index; COO, cell-of-origin 
signature; mBL, molecular Burkitt signature; PAP, pathway activation pattern signature; CC, consensus cluster signature; CI, confidence 
interval. Maj., major; Min.; minor; Mut., mutant.
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ncbi.nlm.nih.gov/geo/, last accessed Oct 1th, 2012. Briefly, 
four independently applied expression-based classifiers 
were attached to each case. These four classifiers were: 
the cell-of-origin signatures (COO) [10,38], the molecular 
Burkitt signatures (mBL) [11], the pathway activation 
pattern signatures (PAP) [12] and the consensus clustering 
signatures (CC) [13]. Nomenclature of the assigned 
signatures followed original publications: for the COO 
signature the subsets were GCB, ABC and unclassified 
[10,38]; for the mBL signature the subsets were mBL, 
non-mBL and intermediate [11]; for the pathway activation 
pattern signature [12] the subsets were BL-PAP, PAP-1, 
PAP-2, PAP-3, PAP-4, Mind-L, and for the CC signatures 
the subsets were oxidative phosphorylation (OxPhos), 
B-cell receptor/proliferation (BCR), host response (HR) 
[13]. When the original description of a classifier was 
based on another gene-expression platform than the one 
used herein (Affymetrix U133A), systematic differences 
were accounted for by applying appropriate adjustment 
algorithms [12,38].
Prior to the assignment of CC labels, study-specific 
effects (e.g., scanner generation, calibration, and platform) 
were adjusted in all models. Briefly, data from Monti et al. 
[13] were shifted and scaled to result in the same mean and 
variance as found across patients in the reference samples 
from Hummel et al. [11]. Subsequently, classification was 
performed by learning a linear 3-Class model with the 
nearest-shrunken centroid algorithm [39] on the data set of 
Monti et al. [13]. Finally this classifier was applied on the 
DLBCL samples from the MMML cohort, assigning the 
appropriate CC labels. Comparisons of each expression-
based signature and subtypes therein were performed as 
uni- and multivariate analysis (see below). 
Clinical features. 
To ascertain the representative nature of this study 
cohort, we applied established clinical criteria with respect 
to treatment: chemotherapeutic classes (CHOP-like, ALL-
like), radiotherapy (yes/no), treatment response (complete 
remission, partial remission, stable disease, progressive 
disease) and relapse (yes/no).
Statistical Analysis.
Statistical analysis consisted of Fisher’s exact test 
(association of mutation status with nominal factors in 
contingency tables) and t test (comparison of age). Due to 
the retrospective nature of this cohort, treatment strategies 
were not uniform [11]. Therefore, the performance 
of established prognostic factors was assessed in the 
study cohort (see Supplemental Figure 2). The Kaplan-
Meier method was used to estimate overall survival and 
uni- as well as multivariate cox proportional hazards 
regression models were used to analyze survival data. 
Given survival times, final life status (alive or dead) and 
one (univariate) or more (multivariate) covariates, the 
regression models produce a baseline survival curve and 
covariate coefficient estimates with their standard errors, 
95% confidence intervals, and significance levels. The 
covariates included in these analyses were (parenthesis 
provide values set to 1): age (≥60), LDH (upper limit of 
normal, >ULN), ECOG (>1), Ann-Arbor stage (AAS; 
III/IV), extranodal involvement (EN; >1), B-symptoms 
(yes); morphology (immunoblastic, ib); COO signature 
(non-GCB); mBL signature (non-mBL); PAP signature 
(non-PAP1); CC signature (non-BCR); SOCS1 status 
(mutation positive); SOCS1 major and SOCS1 minor. 
Moreover, the international prognostic index (IPI) score 
was tested (≥2) [40] and due to partial incompleteness of 
the basic data matrix for individual IPI characteristics in 
some patients, statistical testing was performed assuming 
the more pessimistic situation [i.e. a missing factor was 
set to “absent” (0); therefore some patients with IPI 
0/1 may have higher IPI scores; Supplemental Figure 
2E].  In univariate analyses, covariates were examined 
for their previously acknowledged prognostic impact, 
when applicable. In a second step, we combined factors 
demonstrating significance in univariate assessment in 
a multivariate analysis. Log hazard ratios are provided 
with the 95% confidence intervals (CI); significance was 
defined as P<0.05.
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